Page last updated: 2024-11-05

thalidomide and Pityriasis Rubra Pilaris

thalidomide has been researched along with Pityriasis Rubra Pilaris in 4 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Pityriasis Rubra Pilaris: A chronic skin disease characterized by small follicular papules, disseminated reddish-brown scaly patches, and often, palmoplantar hyperkeratosis. The papules are about the size of a pin and topped by a horny plug.

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Maloney, NJ1
Kim, MM1
Nguyen, KA1
Hisaw, LD1
Worswick, S1
Pellonnet, L1
Beltzung, F1
Franck, F1
Rouanet, J1
D'incan, M1
Cho, M1
Honda, T1
Ueshima, C1
Kataoka, T1
Otsuka, A1
Kabashima, K1
Krase, IZ1
Cavanaugh, K1
Curiel-Lewandrowski, C1

Other Studies

4 other studies available for thalidomide and Pityriasis Rubra Pilaris

ArticleYear
Patient experiences with biologics and apremilast in pityriasis rubra pilaris: A patient survey.
    Dermatologic therapy, 2019, Volume: 32, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Drug Therapy, Combination; Female; Hum

2019
A case of severe pityriasis rubra pilaris with a dramatic response to apremilast.
    European journal of dermatology : EJD, 2018, 02-01, Volume: 28, Issue:1

    Topics: Dermatologic Agents; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Pityriasis Rubra Pil

2018
A Case of Pityriasis Rubra Pilaris Treated Successfully with the Phosphodiesterase-4 Inhibitor Apremilast.
    Acta dermato-venereologica, 2018, Nov-05, Volume: 98, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Middle Aged; Phosphodiesterase 4 Inhibitors

2018
Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.
    JAMA dermatology, 2016, Volume: 152, Issue:3

    Topics: Aged; Biopsy; Drug Resistance; Drug Substitution; Follow-Up Studies; Humans; Male; Phosphodiesterase

2016